Delve Bio and researchers at the University of California, San Francisco collaborated to showcase the potential of metagenomic next-generation sequencing (mNGS) for diagnosing infectious causes of meningitis and encephalitis. A comprehensive study involving over 4,800 patients revealed that mNGS provided valuable insights into the underlying infections. Notably, mNGS yielded definitive diagnoses for over 25% of patients, and 60% of those diagnoses significantly influenced treatment decisions.
Dr. Charles Chiu, Delve Bio’s co-founder, and a renowned infectious disease expert, expressed confidence in mNGS as the most reliable and comprehensive tool for diagnosing infectious diseases. He emphasized the test’s utility in answering over a thousand patients who would have otherwise remained undiagnosed.
Delve Bio’s commitment to enhancing patient care is evident in its flagship cerebrospinal fluid (CSF) testing service, Delve Neuro. This service utilizes an advanced CLIA-certified laboratory and provides robust clinical decision support, delivering results within 48 hours. Delve Neuro is poised to revolutionize the diagnosis of neurological infections by enabling faster and more accurate identification of causative agents.
To further its mission, Delve Bio has appointed Jeff Field, an accomplished genomics industry leader, to helm its commercialization efforts. Mr. Field brings a wealth of experience in launching and marketing groundbreaking healthcare technologies. He believes that mNGS can transform the diagnosis of meningitis and encephalitis, empowering physicians with crucial information to initiate appropriate treatment swiftly.
With its innovative mNGS technology, Delve Bio aims to make this cutting-edge diagnostic tool more accessible. The company’s partnership with UCSF will ensure that the technology pioneered at the prestigious institution reaches a wider patient population, ultimately improving outcomes for those suffering from potentially life-threatening neurological infections.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.